Dr. Logan Wright Zemp, MD

Dr. Zemp practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Zemp's NPI, 1225593148, was assigned on February 5, 2019. Dr. Zemp graduated from University of Alberta in 2014. Dr. Zemp holds Florida license TRN27956.

Dr. Zemp's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Zemp's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Zemp is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Zemp to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zemp practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Zemp's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Zemp is licensed in Florida.

Dmand AI lists bladder removal, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, prostate cancer, urinary endoscopy and urine flow blockage among the conditions Dr. Zemp treats.

CMS data shows 261 Medicare services from Dr. Zemp across 9 procedure codes in 2024, for 183 Medicare patients. Medicare paid $18,996 for them.

CMS counts 183 Medicare patients who saw Dr. Zemp in 2024. The largest group is 65 to 74, with 85 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zemp's median patient age at 72, with 31% women.

In 2024, Dr. Zemp wrote 93 Medicare Part D claims for 58 patients. 97% of them were for generic drugs. CMS names the drug for 51 of them, across 3 drugs with 11 or more claims each, at $723 in total drug cost. In 2023, CMS named 29 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Zemp for performance year 2024, reported as part of a group. Dr. Zemp accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zemp as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 36 papers to Dr. Zemp, published from 2017 to 2025. 2021 was the busiest year, with 9. The most frequent topics are Urinary Bladder Neoplasms, Cystectomy and Carcinoma, Renal Cell. Dr. Zemp has published most often in J Urol. Dr. Zemp's most frequent co-authors are Philippe E. Spiess, MD, Wade J. Sexton, MD and Scott Michael Gilbert, MD.

CMS Open Payments shows 8 general payments to Dr. Zemp from 6 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Astellas Pharma US Inc paid the most, $196.

Dr. Zemp graduated from University of Alberta in 2014.

Dr. Zemp is in network with 7 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.